Cequa™
(cyclosporine ophthalmic solution) 0.09%
Formulated with NCELL™ TECHNOLOGY

How satisfied are your patients with their current prescription treatments for dry eye disease?

Consider CEQUA™, the first and only FDA-approved cyclosporine treatment delivered with NCELL™ technology[1,3]

- NCELL helps improve the delivery of cyclosporine to where it is needed[2,3]
- Significant improvement in tear production at 3 months[1]
- Significant improvement in corneal staining as early as 1 month[2,4]
- The most common adverse reactions reported in >5% of patients were instillation site pain (22%) and conjunctival hyperemia (6%)[1,a]
- In a comfort assessment at 3 minutes post instillation, 90% (Day 0) and 85% (Day 84) of patients had no or mild discomfort[4]

[a]Instillation site pain includes burning and stinging.[2]

Click here to request CEQUA samples

Interested in speaking with a CEQUA Sales Representative?

Request a Rep

INDICATIONS AND USAGE

CEQUA™ (cyclosporine ophthalmic solution) 0.09% is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.

Use with Contact Lenses: CEQUA should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of CEQUA ophthalmic solution.

ADVERSE REACTIONS

The most common adverse reactions reported in greater than 5% of patients were pain on instillation of drops (22%) and conjunctival hyperemia (6%). Other adverse reactions reported in 1% to 5% of patients were blepharitis, eye irritation, headache, and urinary tract infection.

Please see the Full Prescribing Information

References: 1. CEQUA [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; 2018. **2.** Data on file. Cranbury, NJ: Sun Pharmaceutical Industries, Inc. **3.** US Patent 9,937,225 B2. **4.** Tauber J, Schechter BA, Bacharach J, et al. A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. *Clin Ophthalmol.* 2018;12:1921-1929.

PM-US-CQA-0618 09/2020

SUN OPHTHALMICS